Revenue: As of FY2026 Q2, the actual value is USD 490 K, missing the estimate of USD 17.2 M.

EPS: As of FY2026 Q2, the actual value is USD -1.18, missing the estimate of USD -1.0977.

EBIT: As of FY2026 Q2, the actual value is USD -126.55 M.

Financial Position (as of June 30, 2026, compared to December 31, 2025)

Cash, Cash Equivalents, and Marketable Securities

Beam Therapeutics Inc. reported cash, cash equivalents, and marketable securities totaling $1,152,927 thousand as of June 30, 2026, a decrease from $1,245,210 thousand as of December 31, 2025.

Total Assets

Total assets were $1,386,355 thousand as of June 30, 2026, down from $1,481,177 thousand as of December 31, 2025.

Total Liabilities

Total liabilities increased to $318,913 thousand as of June 30, 2026, from $242,819 thousand as of December 31, 2025.

Total Stockholders’ Equity

Total stockholders’ equity decreased to $1,067,442 thousand as of June 30, 2026, from $1,238,358 thousand as of December 31, 2025.

Second Quarter 2026 Financial Performance (compared to Second Quarter 2025)

License and Collaboration Revenue

License and collaboration revenue for the second quarter of 2026 was $490 thousand, a decrease from $8,466 thousand for the second quarter of 2025.

Operating Expenses

Research and Development (R&D) expenses were $95,096 thousand for the second quarter of 2026, down from $101,758 thousand for the second quarter of 2025. General and Administrative (G&A) expenses increased to $31,947 thousand for the second quarter of 2026, from $26,859 thousand for the second quarter of 2025. Total operating expenses were $127,043 thousand for the second quarter of 2026, compared to $128,617 thousand for the second quarter of 2025.

Loss from Operations

Loss from operations for the second quarter of 2026 was - $126,553 thousand, compared to - $120,151 thousand for the second quarter of 2025.

Net Loss

Beam Therapeutics Inc. reported a net loss of - $122,678 thousand for the second quarter of 2026, compared to a net loss of - $102,138 thousand for the second quarter of 2025.

Comprehensive Loss

Comprehensive loss for the second quarter of 2026 was - $123,797 thousand, compared to - $102,288 thousand for the second quarter of 2025.

Six Months Ended June 30, 2026 Financial Performance (compared to Six Months Ended June 30, 2025)

License and Collaboration Revenue

For the six months ended June 30, 2026, license and collaboration revenue was $32,228 thousand, an increase from $15,936 thousand for the same period in 2025.

Operating Expenses

Research and Development (R&D) expenses were $199,620 thousand for the six months ended June 30, 2026, slightly down from $200,574 thousand for the same period in 2025. General and Administrative (G&A) expenses increased to $66,376 thousand for the six months ended June 30, 2026, from $54,799 thousand for the same period in 2025. Total operating expenses were $265,996 thousand for the six months ended June 30, 2026, compared to $255,373 thousand for the same period in 2025.

Loss from Operations

Loss from operations for the six months ended June 30, 2026, was - $233,768 thousand, an improvement from - $239,437 thousand for the same period in 2025.

Net Loss

Net loss for the six months ended June 30, 2026, was - $216,996 thousand, compared to - $210,468 thousand for the same period in 2025.

Comprehensive Loss

Comprehensive loss for the six months ended June 30, 2026, was - $220,296 thousand, compared to - $211,137 thousand for the same period in 2025.

Outlook / Guidance

Beam Therapeutics Inc. expects its cash, cash equivalents, and marketable securities as of June 30, 2026, combined with an anticipated $200 million draw from its facility with Sixth Street, to fund operating expenses and capital expenditure requirements into mid-2029. This funding is projected to support the anticipated launch of risto-cel in Sickle Cell Disease (SCD), the BEAM-302 pivotal development plan in Alpha-1 Antitrypsin Deficiency (AATD), and clinical proof of concept for BEAM-304 in Phenylketonuria (PKU).